Results 131 to 140 of about 20,878 (216)

Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort. [PDF]

Future Oncol
Munir T, Leão D, Messahel B, Srikanthan S, Xu P, Fouad M, Kavanagh C, Tapprich C, Miles O, Scheliga A, Ghia P.   +10 more
europepmc   +1 more source

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma [PDF]

, 2018
Alessandro Broccoli, Beatrice Casadei, Alice Morigi, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, Francesco Pisani, Michele Merli, Carlo Visco, Rossella Paolini, Vittorio Ruggero Zilioli, Luca Baldini, Nicola Di Renzo, Patrizia Tosi, Nicola Cascavilla, Stefano Molica, Fiorella Ilariucci, Gian Matteo Rigolin, Francesco D’Alò, Anna Vanazzi, Elisa Santambrogio, Roberto Marasca, Lucia Mastrullo, Claudia Castellino, Giovanni Desabbata, Ilaria Scortechini, Livio Trentin, Lucia Morello, Lisa Argnani, Pier Luigi Zinzani   +32 more
openalex   +1 more source

PDCD1 as a targetable immune checkpoint hub: therapeutic insights for ibrutinib-resistant CLL management. [PDF]

Clin Exp Med
Kalaki NS, Karimi E, Allaei Rouzbahani K, Ahmadzadeh M, Akrami SM.   +4 more
europepmc   +1 more source

Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells. [PDF]

Int J Biol Sci
Saad AAA, Ge L, Wang H, Xia Y, Li J, Qiao S, Yi C, Wang X, Wang Z, Zhou D, Wang H.   +10 more
europepmc   +1 more source

Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an [PDF]

, 2018
Katharina Arnheim
openalex   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1893-1896, December 2025.
wiley   +1 more source

Influence of CYP2D6, CYP3A, and ABCG2 Genetic Polymorphisms on Ibrutinib Disposition in Chinese Healthy Subjects. [PDF]

Pharmaceuticals (Basel)
Fu K, Wang Y, Duan L, Zhang Z, Qian J, Chen X, Liang Y, Lu C, Zhao D.   +8 more
europepmc   +1 more source

Ibrutinib and PD-1 blockade potentiate mesothelin-targeting CAR-T cell therapy in preclinical models of pancreatic cancer. [PDF]

Clin Cancer Res
Armstrong A, van der Plancke G, Nishiguchi S, Salas-Benito D, Bouffard AA, Goncalves S, Merce AT, Kelly C, Birocchi F, Park S, Leick MB, Horick N, Berger TR, Maus MV, Escobar G.   +14 more
europepmc   +1 more source

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs. [PDF]

J Comp Eff Res
Fitzgerald L, Ghosh S, Bokun A, Lax A, Mu F, Wu E, Lin Y, Shi L, Qureshi ZP, Graf SA.   +9 more
europepmc   +1 more source

Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL). [PDF]

Cell Death Discov
Langpape A, Bonasera D, Stroh J, Reese M, Cartolano M, Liccardi G, von Karstedt S.   +6 more
europepmc   +1 more source